Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||melanoma||not applicable||Ipilimumab||FDA approved||Actionable||In a Phase III trial that supported FDA approval, treatment with Yervoy (ipilimumab) resulted in an improved overall survival of 10.1 months in patients with metastatic melanoma, compared to 6.4 months in those treated with gp100 peptide vaccine alone (PMID: 20525992, PMID: 21900389).||20525992 detail... 21900389|
|Unknown unknown||melanoma||not applicable||Ipilimumab||Phase III||Actionable||In a Phase III trial, adjuvant Opdivo (nivolumab) treatment resulted in improved rate of recurrence-free survival at 12-months compared to Yervoy (ipilimumab) (70.5% vs 60.8%, HR=0.65, P<0.001) in patients with resected stage III or IV melanoma (PMID: 28891423, NCT02388906).||28891423|
|PubMed Id||Reference Title||Details|
|(21900389)||Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.||Full reference...|
|(20525992)||Improved survival with ipilimumab in patients with metastatic melanoma.||Full reference...|
|(28891423)||Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.||Full reference...|
|Yervoy (ipilimumab) FDA Drug Label||Full reference...|